Can a cannabis drug soothe Alzheimer's agitation? new trial aims to find out.
NCT ID NCT07422311
First seen Feb 23, 2026 · Last updated May 03, 2026 · Updated 14 times
Summary
This study tests whether dronabinol, a cannabis-based oral solution, can reduce agitation in people with Alzheimer's disease. About 140 adults aged 50-90 will receive either the drug or a placebo for 12 weeks, followed by a 6-month period where everyone gets dronabinol. The goal is to see if the drug helps calm restlessness and aggression without major side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGITATION IN DEMENTIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Finders Medical Center
Bedford Park, SA Adelaide, 5042, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.